EOG Resources Inc vs uniQure N.V. Ordinary Shares — how do they compare? EOG Resources Inc trades at $155.88 (market cap $80.34B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: EOG Resources Inc is far larger — about 54.3× uniQure N.V. Ordinary Shares's market cap, and EOG Resources Inc pays a 2.66% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EOG | QURE | |
|---|---|---|
Market Cap | $80.34B | $1.48B |
Volume | 2,309,813 | 2,488,780 |
Sector | Energy | Health |
52-Week High | $154.19 | $70.59 |
52-Week Low | $101.78 | $9.03 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $83.69B | $728.62M |
Dividend Yield | 2.66% | — |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $154.19, up 2.45% today, with a bullish technical outlook and strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios are attractive, including a P/E of 11.92 and EV/EBITDA of 6.02. Recent news highlights robust operational execution and a CFO transition.
The outlook remains positive, supported by analyst consensus of a $165 price target and 59% buy ratings. Key risks include oil price volatility and capital expenditure trends. Upside potential hinges on sustained earnings growth and disciplined capital allocation amid energy market fluctuations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →